Published in Int Clin Psychopharmacol on July 01, 2011
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment (2012) 1.00
Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2016) 0.96
Who pioneered the use of antipsychotics in north america? Can J Psychiatry (2015) 0.80
Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). Exp Ther Med (2015) 0.80
Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr (2013) 0.78
Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison. Clin Psychopharmacol Neurosci (2015) 0.78
Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine. Front Psychiatry (2011) 0.77
The ARIQUELI study: potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole. Trials (2013) 0.77
Effects of repeated quetiapine treatment on conditioned avoidance responding in rats. Eur J Pharmacol (2015) 0.75
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry (2007) 3.22
Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry (2007) 2.13
Widespread and sustained cognitive deficits in alcoholism: a meta-analysis. Addict Biol (2012) 1.71
The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res (2005) 1.55
Preserved awareness of their cognitive deficits in patients with schizophrenia: convergent validity of the SSTICS. Schizophr Res (2008) 1.48
Pain relief through expectation supersedes descending inhibitory deficits in fibromyalgia patients. Pain (2009) 1.46
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf (2012) 1.42
Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr Bull (2004) 1.31
Should we treat auditory hallucinations with repetitive transcranial magnetic stimulation? A metaanalysis. Can J Psychiatry (2008) 1.09
Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res (2004) 1.07
Pain inhibition is deficient in chronic widespread pain but normal in major depressive disorder. J Clin Psychiatry (2010) 1.06
A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry (2011) 1.06
Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res (2008) 1.06
Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophr Res (2004) 1.04
Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res (2005) 1.04
Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel) (2012) 1.02
Cerebral activity associated with auditory verbal hallucinations: a functional magnetic resonance imaging case study. J Psychiatry Neurosci (2002) 1.01
Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry (2007) 1.01
CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn (2005) 1.00
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment (2012) 1.00
Predictors of quality of life in schizophrenia. Community Ment Health J (2005) 1.00
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci (2007) 0.99
The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin J Pain (2009) 0.98
Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res (2007) 0.98
Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia. Schizophr Res (2003) 0.98
Effects of cognitive remediation therapies on psychotic symptoms and cognitive complaints in patients with schizophrenia and related disorders: a randomized study. Schizophr Res (2009) 0.97
Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. Eur Arch Psychiatry Clin Neurosci (2014) 0.95
The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry (2004) 0.94
Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res (2013) 0.93
Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf (2008) 0.93
Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res (2005) 0.92
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) (2003) 0.92
Pain perception in schizophrenia: no changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. J Psychiatr Res (2008) 0.90
Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. J Neurosci (2004) 0.90
ERP investigation of study-test background mismatch during face recognition in schizophrenia. Schizophr Res (2011) 0.89
Sexual dimorphism in schizophrenia: is there a need for gender-based protocols? Expert Rev Neurother (2011) 0.89
Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin (2007) 0.89
Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology (2006) 0.89
Pain perception in schizophrenia: evidence of a specific pain response profile. Pain Med (2012) 0.88
Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Front Psychiatry (2013) 0.88
Cannabis and psychosis: what is the link? J Psychoactive Drugs (2007) 0.88
Treating delusional disorder: a comparison of cognitive-behavioural therapy and attention placebo control. Can J Psychiatry (2007) 0.88
Could the use of energy drinks induce manic or depressive relapse among abstinent substance use disorder patients with comorbid bipolar spectrum disorder? Bipolar Disord (2011) 0.87
Agenesis of corpus callosum and emotional information processing in schizophrenia. Front Psychiatry (2012) 0.87
Differential hemodynamic brain activity in schizophrenia patients with blunted affect during quetiapine treatment. J Clin Psychopharmacol (2005) 0.87
Neural correlates of emotional recognition memory in schizophrenia: effects of valence and arousal. Psychiatry Res (2011) 0.87
Sleep habits in middle-aged, non-hospitalized men and women with schizophrenia: a comparison with healthy controls. Psychiatry Res (2010) 0.87
An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses (2013) 0.86
Neural circuitry of impulsivity in a cigarette craving paradigm. Front Psychiatry (2013) 0.85
Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Res (2012) 0.85
A study of theory of mind in paranoid schizophrenia: a theory or many theories? Front Psychol (2012) 0.85
Daily activities, cognition and community functioning in persons with schizophrenia. Schizophr Res (2008) 0.85
Attention and non-REM sleep in neuroleptic-naive persons with schizophrenia and control participants. Psychiatry Res (2006) 0.85
Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res (2009) 0.85
Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin (2008) 0.85
Do patients with schizophrenia attribute mental states in a referential communication task? Cogn Neuropsychiatry (2009) 0.84
The incidence and nature of cerebellar findings in schizophrenia: a quantitative review of fMRI literature. Schizophr Bull (2012) 0.84
The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Res (2004) 0.84
Memory and executive functions in adults with Gilles de la Tourette syndrome and chronic tic disorder. Cogn Neuropsychiatry (2007) 0.84
Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments? Open Rheumatol J (2012) 0.84
Use of the process dissociation procedure to study the contextual effects on face recognition in schizophrenia: familiarity, associative recollection and discriminative recollection. Psychiatry Res (2006) 0.84
Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol (2008) 0.84
Relationship between psychotic and obsessive compulsive symptoms in schizophrenia. Schizophr Res (2009) 0.84
Processing of social emotion in patients with schizophrenia and substance use disorder: an fMRI study. Soc Neurosci (2007) 0.83
Blockade of mGLUR5 receptors differentially alters amphetamine-induced enhancement of locomotor activity and of brain stimulation reward. J Psychopharmacol (2010) 0.83
Mild procedural learning disturbances in neuroleptic-naive patients with schizophrenia. J Neuropsychiatry Clin Neurosci (2003) 0.83
A systematic review on improving cognition in schizophrenia: which is the more commonly used type of training, practice or strategy learning? BMC Psychiatry (2014) 0.83
Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol (2010) 0.82
Genealogy of instruments for prodrome evaluation of psychosis. Front Psychiatry (2013) 0.82
Electrophysiological manifestations of stimulus evaluation, response inhibition and motor processing in Tourette syndrome patients. Psychiatry Res (2009) 0.82
Sex differences in the cerebral function associated with processing of aversive stimuli by schizophrenia patients. Aust N Z J Psychiatry (2007) 0.82
Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments. Cogn Behav Neurol (2004) 0.82
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. Schizophr Res (2005) 0.82
[The role of social support, family burden and satisfaction with services in psychological distress and quality of life of families of individuals with schizophrenia]. Sante Ment Que (2005) 0.82
Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Mov Disord (2010) 0.81
Blockade of ventral midbrain NMDA receptors enhances brain stimulation reward: a preferential role for GluN2A subunits. Eur Neuropsychopharmacol (2013) 0.81
Questioning the specificity of ASRS-v1.1 to accurately detect ADHD in substance abusing populations. J Atten Disord (2011) 0.81
Language functions in right-hemisphere damage and schizophrenia: apparently similar pragmatic deficits may hide profound differences. Brain (2007) 0.81
Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study. Psychiatry Res (2007) 0.81
Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair. CNS Neurosci Ther (2013) 0.81
Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.81
Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. Am J Drug Alcohol Abuse (2008) 0.81
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opin Drug Saf (2012) 0.81
Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin (2006) 0.81
Sexual dimorphism of spatial working memory profiles in schizophrenia. Cogn Neuropsychiatry (2010) 0.81
Opposite modulation of brain stimulation reward by NMDA and AMPA receptors in the ventral tegmental area. Front Syst Neurosci (2013) 0.80
Genes and memory: the neuroanatomical correlates of emotional memory in monozygotic twin discordant for schizophrenia. Brain Cogn (2004) 0.80
Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Aust N Z J Psychiatry (2007) 0.80
Brain-behavior relations during motor processing in chronic tic and habit disorder. Cogn Behav Neurol (2005) 0.80
Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin (2007) 0.80